Vesicle Therapeutics Inc.
The University of Colorado Connection
鈥媀esicle Therapeutics is a Longmont-based biotechnology company developing programmable extracellular vesicles, known as 鈥済ectosomes,鈥 to deliver macromolecular therapeutics to intracellular targets. Founded by 听(蜜桃传媒破解版下载 Biochemistry), the company builds upon research from his lab focused on engineering vesicles for targeted delivery. Gectosomes are designed to encapsulate therapeutic proteins and nucleic acids, facilitating their delivery into cells and enabling applications such as genome editing and treatment of diseases like cancer and neurodegeneration. Vesicle Therapeutics has received National Institutes of Health (NIH) SBIR and STTR funding to advance its platform, including projects targeting familial hypercholesterolemia and neurodegenerative diseases.
Funding Status and Investment Opportunities
- Industry Applications: Health and Wellness, Biotech鈥, Therapeutics
- Funding Stage: Seed Round
- Contact for Investment Inquiries: , curtis.woodard@vesicletherapeutics.com
In the News
Technology Development Funding
U.S. National Institutes of Health (NIH)
听听 听This page was last updated on March 12, 2025. Please email vpnews@colorado.edu for corrections or updates
The Insider Investor E-Newsletter
Media Inquiries
For marketing inquiries and news tips, contact Daniel Leonard,听senior marketing and communications specialist for Venture Partners at 蜜桃传媒破解版下载.
For media inquiries, please visit .